Loading
journalsJournal
International journal of clinical oncology
The official journal of the Japan Society of Clinical Oncology, publishing clinical trials and other clinical cancer research in English. Read by oncologists in Japan and internationally.
Also called: Int J Clin OncolIJCO
Overview
International Journal of Clinical Oncology (IJCO) is the official journal of the Japan Society of Clinical Oncology and is published by Springer under a hybrid publishing model. Its aims welcome original and review papers on all aspects of clinical oncology reporting novel and timely investigations, encourage reports of clinical trials and give priority to high-quality clinical articles such as prospective randomised studies over retrospective ones; basic and translational studies are accepted only when they have obvious clinical significance, and society membership is not required to submit. Papers are peer reviewed by at least two referees and the Editors. The NLM Catalog records a start in 1996, publication for the society by Springer-Verlag Tokyo since 1998, six issues a year and MEDLINE indexing.
Publisher
Springer (Springer Japan) · Japan Society of Clinical Oncology
Scope
clinical oncology
Access model
hybrid
Founded
1996
ISSN
1341-9625
observational202411 citations
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
This is the paper Europe PMC returns for registry id NCT05101096 with the most citations, so it is the natural first reading for anyone following the ASCENT-J02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
rct202314 citations
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
A second publication from the CheckMate 227 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
observationalInternational journal of clinical oncology 202411 citations
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
This is the paper Europe PMC returns for registry id NCT05101096 with the most citations, so it is the natural first reading for anyone following the ASCENT-J02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
rctInternational journal of clinical oncology 202314 citations
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
A second publication from the CheckMate 227 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
Similar pages
- JournalOncology
Shares Clinical trial, PubMed & Europe PMC.
- JournalNeoplasia
Shares Clinical trial, PubMed & Europe PMC.
- JournalAsia-Pacific journal of clinical oncology
Shares Clinical trial, PubMed & Europe PMC.
- JournalJapanese journal of clinical oncology
Shares Clinical trial, PubMed & Europe PMC.
- JournalCurrent problems in cancer
Shares Clinical trial, PubMed & Europe PMC.
- JournalAmerican journal of clinical oncology
Shares Clinical trial, PubMed & Europe PMC.
- JournalCancer treatment and research communications
Shares Clinical trial, PubMed & Europe PMC.
- TermBlinded trial
Shares Randomised trial, Clinical trial.